

Bravecto[®]

Page 1 of 5

Section 1: Identification of the Substance and Supplier		
Product name	Bravecto	
	This SDS relates to the following marketed products:	
	Bravecto for Very Small Dogs (2 - 4.5 kg) Bravecto for Small Dogs (>4.5 - 10 kg) Bravecto for Medium-Sized Dogs (>10 - 20 kg) Bravecto for Large Dogs (>20 - 40 kg) Bravecto for Extra Large Dogs (>40 - 56 kg)	
Recommended use	For oral flea and tick treatment in dogs	
Company details	Schering-Plough Animal Health Limited 33 Whakatiki Street, Upper Hutt 5018, New Zealand	
	Phone: 0800 800 543 Fax: 0800 808 100 Website: www.msd-animal-health.co.nz Hours: 8 am – 5 pm, Mon – Fri	
Emergency telephone	0800 764 766 (0800 POISON) 24 hours human health 0800 243 622 (0800 CHEMCALL) 24 hours	
Date of preparation	April 2019	
	Section 2: Hazards Identification	
Hazard classifications	6.1E: Acute toxicant 6.3B: Skin irritant 9.1A: Aquatic ecotoxicant	
GHS Pictogram:		
Signal word	Warning	
Hazard statement	H303: May be harmful if swallowed. H316: Causes mild skin irritation. H410: Very toxic to aquatic life with long lasting effects.	
Prevention statement	P102: Keep out of reach of children. P103: Read label before use. P273: Avoid release to the environment.	
Response statement	P101: If medical advice is needed, have product container or label at hand. P332 + P313: If skin irritation occurs: Get medical advice/ attention. P391: Collect spillage.	
Disposal	P501: Dispose of product, packaging and waste at an approved landfill or other approved facility.	

Section 3:	Compo	sition/Info	rmation on	Ingredients

Chemical name	CAS number	Concentration
Fluralaner	846731–61-3	13.64%
Sodium lauryl sulphate	151-21-3	<5 %
Disodium Pamoate	6640-22-8	<5 %



Page 2 of 5

Bravecto[®]

	Section 4: First Aid Measures
Necessary first aid measures	SKIN CONTACT While wearing protective gloves, carefully remove any contaminated clothing, including shoes, and wash skin thoroughly with soap and water. If irritation or symptoms occur or persist, consult a doctor.
	EYE CONTACT Immediately rinse eyes thoroughly with plenty of water. If wearing contact lenses, remove only after initial rinse, and continue rinsing eyes for at least 15 minutes. If irritation occurs or persists, consult a doctor.
	INGESTION Rinse mouth with water and drink a glass of water. DO NOT induce vomiting unless under the direction of a qualified medical professional or National Poisons Centre. If symptoms persist, consult a doctor.
	INHALATION Remove to fresh air. If any trouble breathing, get immediate medical attention. Administer artificial respiration if breathing has ceased. If irritation or symptoms occur or persist, consult a doctor.
Required instructions	For advice contact the National Poisons Centre 0800 POISON (0800 764 766) or a doctor.
Workplace facilities	Emergency showers and eyewashes may be warranted depending on quantity and type of use.
	Section 5: Fire Fighting Measures
Type of hazard	Not classified as flammable
Fire hazard properties	Not applicable
Regulatory requirements	Not applicable
Extinguishing media and methods	Carbon dioxide (CO2), extinguishing powder or water spray.
Hazchem code	2X
Recommended protective clothing	Wear full protective clothing and self-contained breathing apparatus (SCBA).
	Section 6: Accidental Release Measures
Personal Precautions	Avoid contact with skin, eyes and clothing. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing.
Environmental Precautions	Prevent spilled material from flowing onto adjacent land or into streams, ponds, or lakes. Avoid release to the environment.
Emergency procedures	Wear chemical resistant gloves and overalls, facemask or goggles. Prevent further spillage. Recover and salvage product where possible. Otherwise sweep up and collect and place in sealable container for disposal. Seek advice from the local authority regarding disposal. Avoid contamination of any water source with product or empty container.



Bravecto[®]

Page 3 of 5

Precautions for safe handling	Avoid contact with skin, eyes, and mucosa. Keep containers adequately sealed during material transfer, transport, or when not in use. See Section 8 (Exposure Controls) for additional guidance.
Regulatory requirements	Signage required where quantities greater than 100 kg are present. Emergency Plan required where quantities greater than 100 kg are present.
Handling practices	Avoid contact with skin. Keep containers adequately sealed during material transfer, transport, or when not in use.
Certified handlers	Not required
Conditions for safe storage	Store in original container in a cool, dry, ventilated place away from direct heat or direct sunlight. Keep container sealed when not in use. Keep out of reach of children.
Store site requirements	Store below 30°C. Protect from humidity and light. DO NOT REFRIGERATE.
Packaging	PG III
	Section 8: Exposure Control/Personal Protection
Occupational exposure	No WES is set for this substance at this time.
limits	
Imits Application in the workplace	Ensure adequate ventilation. Keep container sealed when not in use.
Application in the	Ensure adequate ventilation. Keep container sealed when not in use. No TEL or EEL is set for this substance at this time.
Application in the workplace Exposure standards	

Section 9: Physical and Chemical Properties

Appearance	Light to dark brown chewable tablet
Boiling Point	Not determined
Melting/Softening point	Not determined
Vapour Pressure	Not determined
Specific Gravity	Not determined
Solubility (H ₂ O)	Not determined



Page 4 of 5

Bravecto[®]

Percent Volatiles Not determined Flash Point Not determined Not determined **Evaporation Rate** Section 10: Stability and Reactivity Stability of the substance Stable under normal conditions. No hazardous reactions known. Conditions to avoid Keep away from heat, sparks, open flame and direct sunlight. Material to avoid Avoid food products. Strong acids and bases. Strong oxidizers. Hazardous decomposition No dangerous decomposition is expected if used according to manufacturer's products specifications. Section 11: Toxicological Information Acute effects for individual ingredients only ORAL Fluralaner: LD50 >2000 mg/kg (rat); Sodium lauryl sulphate: LD50 1288 mg/kg (rat) Fluralaner: LD50 >2000 mg/kg (rat); DFRMAI Sodium lauryl sulphate: LD50 580 mg/kg (rabbit) (IUCLID) Disodium Pamoate: Skin inflammation is characterized by itching, scaling, reddening, or, occasionally, blistering. Inflammation of the eye is characterized by redness, watering, and itching. TEL No TEL is set for this substance at this time.

Chronic/long term effects for individual ingredients only

Section 12: Environmental Information

Effects for individual ingredients only

ΑQUATIC	Fluralaner: 96-hr LC50 (Common carp): 2 mg/L 48-hr EC50 (Daphnia magna): 0.0001 - 0.01 mg/L 72-hr EC50 (P. subcapitata): >10 mg/L
TERRESTRIAL INVERTEBRATES	No data
EEL	No EEL is set for this substance at this time.

Section 13: Disposal Considerations

Disposal information	Disposal Dispose of unused contents in a suitable landfill. Where possible, dispose of unused product through AgRecovery Chemicals. Avoid contamination of any water source or the environment with product or empty container.
	Container Disposal Dispose of empty container by puncturing and burying in a suitable landfill. Where possible, recycle through AgRecovery. Do NOT burn.
Reference	Current version of NZS 8409 Management of Agrichemicals



Bravecto[®]

Page 5 of 5

Section 14: Transport Information

UN Number	3077
UN proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Isoxazoline derivative – Fluralaner)
UN dangerous goods class and subsidiary risk	9
UN Packaging Group	PG III
Environmental hazards	Marine pollutant
Special precautions when transporting the substance	¥22
	Section 15: Regulatory Information
Regulatory status	ACVM Registration No: A11019 For conditions of registration see www.foodsafety.govt.nz
	HSNO Approval Code: HSR100757. For a full listing of controls see www.epa.govt.nz
	Section 16: Other Information
Additional information	Bravecto is a registered trademark.
Schering-Plough Animal Health Ltd kno	wn as MSD Animal Health, is a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA.

Schering-Plough Animal Health Ltd known as MSD Animal Health, is a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. Schering-Plough Animal Health Limited urges each user or recipient of this SDS to read the entire data sheet to become aware of the potential hazards associated with this material. This SDS summarises, at the date of issue, our best knowledge of the health and safety hazard information. Although reasonable care has been taken in the preparation of this document, Schering-Plough Animal Health Ltd extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequence of its use. Each individual should make a determination as to the suitability of the information for their particular purpose(s).